A day after receiving orphan drug designation for remdesivir that gave it a fast track to approval and lengthened its market exclusivity, Gilead is requesting the FDA to rescind the designation. Critics had previously charged that the designation could make the drug less affordable.

LEAVE A REPLY

Please enter your comment!
Please enter your name here